The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Frankfurter Institut für Klinische Krebsforschung IKF GmbH; Immutep
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Sylvie Lorenzen
No Relationships to Disclose
 
Jorge Riera
Consulting or Advisory Role - Merck; MSD
Travel, Accommodations, Expenses - Amgen; Novartis
 
Karel Caca
No Relationships to Disclose
 
Christian Mueller
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb Germany; Lilly
 
Daniel E Stange
Patents, Royalties, Other Intellectual Property - Patent pending for FLOT chemotherapy testing using organoids. Patent registration number #10 2022 132 767.1. Patent title: "Verfahren zur Prädiktion eines patientenindividuellen Ansprechen auf das FLOT-Chemotherapie-Schema".
 
Thomas Zander
Consulting or Advisory Role - AstraZeneca; BMS; MSD Oncology; Novartis; Pfizer; Roche
 
Claus Bolling
No Relationships to Disclose
 
Nils Homann
Consulting or Advisory Role - Amgen; BMS GmbH & Co. KG; Lilly; MSD Oncology; SERVIER
 
Jochen Gaedcke
No Relationships to Disclose
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Meyers-Squibb; Daiichi Sankyo; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck Serono
 
Patrick Michl
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen; Falk Pharma; MCI Deutschland; MSD
 
Wolfgang Blau
No Relationships to Disclose
 
Kai Wille
No Relationships to Disclose
 
Christine Koch
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Daniel Wilhelm Mueller
No Relationships to Disclose
 
Ulli Simone Bankstahl
No Relationships to Disclose
 
Stefan Paul Mönig
No Relationships to Disclose
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)